Twenty years in oncolytic virus research and development
for a new chapter of tumor immunotherapy
Recombinant protein vaccine
Nucleic acid vaccine
Developed multiple indication products based on the oncolytic virus immunotherapy and vaccine platform
Binhui Biopharmaceutical raised the strategic invest...
Binhui Biopharmaceutical has been granted a patent f...
Binhui Biopharmaceutical’s oncolytic virus candidate...
BS001 (OH2) injection for the treatment of recurrent...
Copyright © 2018 BINHUI BIOPHARM All Rights Reserved All Rights Reserved